Names | |
---|---|
IUPAC name
7,12-Dimethylbenzo[a]phenanthrene
|
|
Other names
7,12-Dimethylbenzanthracene; 7,12-Dimethyltetraphene; 1,4-Dimethyl-2,3-benzophenanthrene
|
|
Identifiers | |
3D model (Jmol)
|
|
ChEBI | |
ChemSpider | |
ECHA InfoCard | 100.000.326 |
PubChem CID
|
|
|
|
|
|
Properties | |
C20H16 | |
Molar mass | 256.35 g·mol−1 |
Melting point | 122 to 123 °C (252 to 253 °F; 395 to 396 K) |
Hazards | |
Main hazards | T (Toxic) |
R-phrases | R45 R22 |
S-phrases | S53 S36/37 S45 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
|
what is ?) | (|
Infobox references | |
7,12-Dimethylbenz[a]anthracene (DMBA) is an immunosuppressor and a powerful organ-specific laboratory carcinogen. DMBA is widely used in many research laboratories studying cancer. DMBA serves as a tumor initiator. Tumor promotion can be induced with treatments of 12-O-tetradecanoylphorbol-13-acetate (TPA) in some models of two-stage carcinogenesis. This allows for a greatly accelerated rate of tumor growth, making many cancer studies possible.